IP Library Granted Patent US 12,529,164
Granted Patent B2
US 12,529,164 · App. 17/856,679 · Granted Jan 20, 2026

Rationally designed, synthetic antibody libraries and uses therefor

Inventors: Maximiliano Vasquez (Lebanon, NH); Michael Feldhaus (Lebanon, NH); Tillman U. Gerngross (Lebanon, NH); K. Dane Wittrup (Lebanon, NH)
Assignee: Adimab, LLC
C40B40/08C07K16/00C07K16/005C12N15/1093C07K2317/565C07K2317/567C40B50/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,529,164
App. No.
17/856,679
Granted
Jan 20, 2026
Kind
B2
Abstract

The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system, with or without DH segments derived from other species, and are based on rational design informed by examination of publicly available databases of antibody sequences.

Claims (14)

1 . A method of isolating one or more host cells from a population of host cells, the population of host cells comprising synthetic polynucleotides that encode an antibody heavy chain or alternative scaffold containing at least about 10 6 unique antibody CDRH3 amino acid sequences, the method comprising:

(i) expressing a polypeptide comprising a CDRH3 sequence in one or more host cells, wherein the CDRH3 sequence comprises:

(a) an N1 amino acid sequence of 0 to about 3 amino acids, wherein each amino acid of the N1 amino acid sequence is among the 12 most frequently occurring amino acids at the corresponding position in N1 amino acid sequences of CDRH3 amino acid sequences that are functionally expressed by B cells,

(b) a non-human CDRH3 DH amino acid sequence, N- and C-terminal truncations thereof, or a sequence of at least about 80% identity to any of them,

(c) an N2 amino acid sequence of 0 to about 3 amino acids, wherein each amino acid of the N2 amino acid sequence is among the 12 most frequently occurring amino acids at the corresponding position in N2 amino acid sequences of CDRH3 amino acid sequences that are functionally expressed by B cells, and

(d) a human CDRH3 H3-JH amino acid sequence, N-terminal truncations thereof, or a sequence of at least about 80% identity to any of them;

(ii) contacting the host cells with one or more antigens; and

(iii) isolating one or more host cells having antibodies that bind to the one or more antigens.

2 . The method of claim 1 , wherein the non-human CDRH3 DH amino acid sequence is a sequence from a vertebrate species.

3 . The method of claim 2 , wherein the vertebrate species is selected from the group consisting of Mus musculus, Camelus sp., Llama sp., Camelidae sp., Raja sp., Ginglymostoma sp., Carcharhinus sp., Heterodontus sp., Hydrolagus sp., Ictalurus sp., Gallus sp., Bos sp., Marmaronetta sp., Aythya sp., Netta sp., Equus sp., Pentalagus sp., Bunolagus sp., Nesolagus sp., Romerolagus sp., Brachylagus sp., Sylvilagus sp., Oryctolagus sp., Poelagus sp., Ovis sp., Sus sp., Gadus sp., Salmo sp., Oncorhynchus sp., Macaca sp., Rattus sp., Pan sp., Hexanchus sp., Heptranchias sp., Notorynchus sp., Chlamydoselachus sp., Heterodontus sp., Pristiophorus sp., Pliotrema sp., Squatina sp., Carcharia sp., Mitsukurina sp., Lamma sp., Isurus sp., Carcharodon sp., Cetorhinus sp., Alopias sp., Nebrius sp., Stegostoma sp., Orectolobus sp., Eucrossorhinus sp., Sutorectus sp., Chiloscyllium sp., Hemiscyllium sp., Brachaelurus sp., Heteroscyllium sp., Cirrhoscyllium sp., Parascyllium sp., Rhincodon sp., Apristurus sp., Atelomycterus sp., Cephaloscyllium sp., Cephalurus sp., Dichichthys sp., Galeus sp., Halaelurus sp., Haploblepharus sp., Parmaturus sp., Pentanchus sp., Poroderna sp., Schroederichthys sp., Scyliorhinus sp., Pseudotriakis sp., Scylliogaleus sp., Furgaleus sp., Hemitriakis sp., Mustelus sp., Triakis sp., Iago sp., Galeorhinus sp., Hypogaleus sp., Chaenogaleus sp., Hemigaleus sp., Paragaleus sp., Galeocerdo sp., Prionace sp., Sciolodon sp., Loxodon sp., Rhizoprionodon sp., Aprionodon sp., Negaprion sp., Hypoprion sp., Carcharhinus sp., Isogomphodon sp., Triaenodon sp., Sphyrna sp., Echinorhinus sp., Oxynotus sp., Squalus sp., Centroscyllium sp., Etmopterus sp., Centrophorus sp., Cirrhigaleus sp., Deania sp., Centroscymnus sp., Scymnodon sp., Dalatias sp., Euprotomicrus sp., Isistius sp., Squaliolus sp., Heteroscymnoides sp., Somniosus sp., and Megachasma sp.

4 . The method of claim 1 , wherein the one or more host cells are yeast cells.

5 . The method of claim 4 , wherein the yeast cells are S. cerevisiae cells.

6 . The method of claim 1 , wherein the N1 amino acid sequence comprises G, P, R, A, S, L, T, V, GG, GP, GR, GA, GS, GL, GT, GV, PG, RG, AG, SG, LG, TG, VG, PP, PR, PA, PS, PL, PT, PV, RP, AP, SP, LP, TP, VP, GGG, GPG, GRG, GAG, GSG, GLG, GTG, GVG, PGG, RGG, AGG, SGG, LGG, TGG, VGG, GGP, GGR, GGA, GGS, GGL, GGT, GGV, D, E, F, H, I, K, M, Q, W, Y, AR, AS, AT, AY, DL, DT, EA, EK, FH, FS, HL, HW, IS, KV, LD, LE, LR, LS, LT, NR, NT, QE, QL, QT, RA, RD, RE, RF, RH, RL, RR, RS, RV, SA, SD, SE, SF, SI, SK, SL, SQ, SR, SS, ST, SV, TA, TR, TS, TT, TW, VD, VS, WS, YS, AAE, AYH, DTL, EKR, ISR, NTP, PKS, PRP, PTA, PTQ, REL, RPL, SAA, SAL, SGL, SSE, TGL, or WGT.

7 . The method of claim 1 , wherein the N2 amino acid sequence comprises G, P, R, A, S, L, T, V, GG, GP, GR, GA, GS, GL, GT, GV, PG, RG, AG, SG, LG, TG, VG, PP, PR, PA, PS, PL, PT, PV, RP, AP, SP, LP, TP, VP, IG, KG, GW, FP, EG, GGG, GPG, GRG, GAG, GSG, GLG, GTG, GVG, PGG, RGG, AGG, SGG, LGG, TGG, VGG, GGP, GGR, GGA, GGS, GGL, GGT, GGV, D, E, F, H, I, K, M, Q, W, Y, AR, AS, AT, AY, DL, DT, EA, EK, FH, FS, HL, HW, IS, KV, LD, LE, LR, LS, LT, NR, NT, QE, QL, QT, RA, RD, RE, RF, RH, RL, RR, RS, RV, SA, SD, SE, SF, SI, SK, SL, SQ, SR, SS, ST, SV, TA, TR, TS, TT, TW, VD, VS, WS, YS, AAE, AYH, DTL, EKR, ISR, NTP, PKS, PRP, PTA, PTQ, REL, RPL, SAA, SAL, SGL, SSE, TGL, or WGT.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2024
From: VASQUEZ, MAXIMILIANO; FELDHAUS, MICHAEL; GERNGROSS, TILLMAN U.; WITTRUP, K. DANE
To: ADIMAB, LLC
Reel/Frame 069580/0566 →
MERGER AND CHANGE OF NAME Recorded Dec 13, 2024
From: ADIMAB, INC.; ADIMAB, LLC
To: ADIMAB, LLC
Reel/Frame 069580/0657 →
Continuity (8)
Continuation 17534006 · Nov 23, 2021
Continuation 17231414 · Apr 15, 2021
Division 16236259 · Dec 28, 2018
Division 14256126 · Apr 18, 2014
Continuation 12404059 · Mar 13, 2009
Continuation In Part 12210072 · Sep 12, 2008
Provisional Application 60993785 · Sep 14, 2007
Related Publication 20230348901A1 · Nov 2, 2023
References Cited (400)
US 4230685A · Senyei et al. · 1980 [cited by applicant]
US 4452773A · Molday · 1984 [cited by applicant]
US 4661454A · Botstein et al. · 1987 [cited by applicant]
US 4770183A · Groman et al. · 1988 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 4959317A · Sauer · 1990 [cited by applicant]
US 5118605A · Urdea · 1992 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5283173A · Fields et al. · 1994 [cited by applicant]
US 5380833A · Urdea · 1995 [cited by applicant]
US 5506121A · Skerra et al. · 1996 [cited by applicant]
US 5525490A · Erickson et al. · 1996 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5571698A · Ladner et al. · 1996 [cited by applicant]
US 5618920A · Robinson et al. · 1997 [cited by applicant]
US 5658727A · Barbas et al. · 1997 [cited by applicant]
US 5688666A · Bass et al. · 1997 [cited by applicant]
US 5695941A · Brent et al. · 1997 [cited by applicant]
US 5712120A · Rodriguez et al. · 1998 [cited by applicant]
US 5723323A · Kauffman et al. · 1998 [cited by applicant]
US 5723584A · Schatz · 1998 [cited by applicant]
US 5733743A · Johnson et al. · 1998 [cited by applicant]
US 5739281A · Thogersen et al. · 1998 [cited by applicant]
US 5750373A · Garrard et al. · 1998 [cited by applicant]
US 5767260A · Whitlow et al. · 1998 [cited by applicant]
US 5780279A · Matthews et al. · 1998 [cited by applicant]
US 5798208A · Crea · 1998 [cited by applicant]
US 5811238A · Stemmer et al. · 1998 [cited by applicant]
US 5814476A · Kauffman et al. · 1998 [cited by applicant]
US 5817483A · Kauffman et al. · 1998 [cited by applicant]
US 5821047A · Garrard et al. · 1998 [cited by applicant]
US 5824514A · Kauffman et al. · 1998 [cited by applicant]
US 5830663A · Embleton et al. · 1998 [cited by applicant]
US 5837242A · Holliger et al. · 1998 [cited by applicant]
US 5837500A · Ladner et al. · 1998 [cited by applicant]
US 5840479A · Little et al. · 1998 [cited by applicant]
US 5846765A · Matthews et al. · 1998 [cited by applicant]
US 5858657A · Winter et al. · 1999 [cited by applicant]
US 5858671A · Jones · 1999 [cited by applicant]
US 5863765A · Berry et al. · 1999 [cited by applicant]
US 5866344A · Georgiou · 1999 [cited by applicant]
US 5869250A · Cheng et al. · 1999 [cited by applicant]
US 5871907A · Winter et al. · 1999 [cited by applicant]
US 5872215A · Osbourne et al. · 1999 [cited by applicant]
US 5874239A · Schatz · 1999 [cited by applicant]
US 5885793A · Griffiths et al. · 1999 [cited by applicant]
US 5888773A · Jost et al. · 1999 [cited by applicant]
US 5917018A · Thogersen et al. · 1999 [cited by applicant]
US 5922545A · Mattheakis et al. · 1999 [cited by applicant]
US 5928868A · Liu et al. · 1999 [cited by applicant]
US 5932433A · Schatz · 1999 [cited by applicant]
US 5935831A · Quax et al. · 1999 [cited by applicant]
US 5948620A · Hurd et al. · 1999 [cited by applicant]
US 5955275A · Kamb · 1999 [cited by applicant]
US 5962255A · Griffiths et al. · 1999 [cited by applicant]
US 5965368A · Vidal et al. · 1999 [cited by applicant]
US 5969108A · McCafferty et al. · 1999 [cited by applicant]
US 5976862A · Kauffman et al. · 1999 [cited by applicant]
US 5994515A · Hoxie · 1999 [cited by applicant]
US 5994519A · Osbourn et al. · 1999 [cited by applicant]
US 6010884A · Griffiths et al. · 2000 [cited by applicant]
US 6017732A · Jespers et al. · 2000 [cited by applicant]
US 6022729A · Steinbuchel et al. · 2000 [cited by applicant]
US 6027910A · Klis et al. · 2000 [cited by applicant]
US 6040136A · Garrard et al. · 2000 [cited by applicant]
US 6057098A · Buechler et al. · 2000 [cited by applicant]
US 6057101A · Nandabalan et al. · 2000 [cited by applicant]
US 6072036A · Marasco et al. · 2000 [cited by applicant]
US 6072039A · Haase et al. · 2000 [cited by applicant]
US 6083693A · Nandabalan et al. · 2000 [cited by applicant]
US 6103493A · Skerra et al. · 2000 [cited by applicant]
US 6114147A · Frenken et al. · 2000 [cited by applicant]
US 6132963A · Brent et al. · 2000 [cited by applicant]
US 6140471A · Johnson et al. · 2000 [cited by applicant]
US 6159705A · Trueheart et al. · 2000 [cited by applicant]
US 6171795B1 · Korman et al. · 2001 [cited by applicant]
US 6172197B1 · McCafferty et al. · 2001 [cited by applicant]
US 6180336B1 · Osbourn et al. · 2001 [cited by applicant]
US 6187535B1 · LeGrain et al. · 2001 [cited by applicant]
US 6200759B1 · Dove et al. · 2001 [cited by applicant]
US 6225447B1 · Winter et al. · 2001 [cited by applicant]
US 6248516B1 · Winter et al. · 2001 [cited by applicant]
US 6265552B1 · Schatz · 2001 [cited by applicant]
US 6291158B1 · Winter et al. · 2001 [cited by applicant]
US 6291159B1 · Winter et al. · 2001 [cited by applicant]
US 6291160B1 · Lerner et al. · 2001 [cited by applicant]
US 6291161B1 · Lerner et al. · 2001 [cited by applicant]
US 6291650B1 · Winter et al. · 2001 [cited by applicant]
US 6300064B1 · Knappik et al. · 2001 [cited by applicant]
US 6300065B1 · Kieke et al. · 2001 [cited by applicant]
US 6312916B1 · Kopetzki et al. · 2001 [cited by applicant]
US 6319690B1 · Little et al. · 2001 [cited by applicant]
US 6342588B1 · Osbourn et al. · 2002 [cited by applicant]
US 6358733B1 · Motwani et al. · 2002 [cited by applicant]
US 6368813B1 · Reznik et al. · 2002 [cited by applicant]
US 6406863B1 · Zhu et al. · 2002 [cited by applicant]
US 6410246B1 · Zhu et al. · 2002 [cited by applicant]
US 6410271B1 · Zhu et al. · 2002 [cited by applicant]
US 6420113B1 · Buechler et al. · 2002 [cited by applicant]
US 6423538B1 · Wittrup et al. · 2002 [cited by applicant]
US 6489123B2 · Osbourn et al. · 2002 [cited by applicant]
US 6492107B1 · Kauffman et al. · 2002 [cited by applicant]
US 6492123B1 · Holliger et al. · 2002 [cited by applicant]
US 6492160B1 · Griffiths et al. · 2002 [cited by applicant]
US 6521404B1 · Griffiths et al. · 2003 [cited by applicant]
US 6531580B1 · Huse et al. · 2003 [cited by applicant]
US 6544731B1 · Griffiths et al. · 2003 [cited by applicant]
US 6545142B1 · Winter et al. · 2003 [cited by applicant]
US 6555313B1 · Griffiths et al. · 2003 [cited by applicant]
US 6569641B1 · Kauffman et al. · 2003 [cited by applicant]
US 6582915B1 · Griffiths et al. · 2003 [cited by applicant]
US 6589527B1 · Winter et al. · 2003 [cited by applicant]
US 6589741B2 · Pluckthun et al. · 2003 [cited by applicant]
US 6593081B1 · Griffiths et al. · 2003 [cited by applicant]
US 6610472B1 · Zhu et al. · 2003 [cited by applicant]
US 6653443B2 · Zhang et al. · 2003 [cited by applicant]
US 6664048B1 · Wanker et al. · 2003 [cited by applicant]
US 6680192B1 · Lerner et al. · 2004 [cited by applicant]
US 6696245B2 · Winter et al. · 2004 [cited by applicant]
US 6696248B1 · Knappik et al. · 2004 [cited by applicant]
US 6696251B1 · Wittrup et al. · 2004 [cited by applicant]
US 6699658B1 · Wittrup et al. · 2004 [cited by applicant]
US 6706484B1 · Knappik et al. · 2004 [cited by applicant]
US 6750042B2 · Summers et al. · 2004 [cited by applicant]
US 6753136B2 · Lohning · 2004 [cited by applicant]
US 6806079B1 · McCafferty et al. · 2004 [cited by applicant]
US 6828422B1 · Achim et al. · 2004 [cited by applicant]
US 6833441B2 · Wang et al. · 2004 [cited by applicant]
US 6841359B2 · Szostak et al. · 2005 [cited by applicant]
US 6846634B1 · Tomlinson et al. · 2005 [cited by applicant]
US 6916605B1 · McCafferty et al. · 2005 [cited by applicant]
US 6919183B2 · Fandl et al. · 2005 [cited by applicant]
US 6969586B1 · Lerner et al. · 2005 [cited by applicant]
US 7005503B2 · Hua et al. · 2006 [cited by applicant]
US 7037706B1 · Barrett et al. · 2006 [cited by applicant]
US 7063943B1 · McCafferty et al. · 2006 [cited by applicant]
US 7083945B1 · Chen et al. · 2006 [cited by applicant]
US 7094571B2 · Harvey et al. · 2006 [cited by applicant]
US 7112439B2 · Johnson et al. · 2006 [cited by applicant]
US 7118915B2 · Vogt et al. · 2006 [cited by applicant]
US 7138253B2 · Szostak et al. · 2006 [cited by applicant]
US 7166423B1 · Miltenyi et al. · 2007 [cited by applicant]
US 7172877B2 · Ting · 2007 [cited by applicant]
US 7189841B2 · Lerner et al. · 2007 [cited by applicant]
US 7198935B1 · Bartosch et al. · 2007 [cited by applicant]
US 7208293B2 · Ladner et al. · 2007 [cited by applicant]
US 7229757B2 · Barrett et al. · 2007 [cited by applicant]
US 7252998B2 · Skerra et al. · 2007 [cited by applicant]
US 7282475B2 · Porter et al. · 2007 [cited by applicant]
US 7302146B2 · Turner et al. · 2007 [cited by applicant]
US 7315019B2 · Turner et al. · 2008 [cited by applicant]
US 7335019B2 · Suzuki et al. · 2008 [cited by applicant]
US 7355008B2 · Stavenhagen et al. · 2008 [cited by applicant]
US 7371849B2 · Honda et al. · 2008 [cited by applicant]
US 7435553B2 · Fandl et al. · 2008 [cited by applicant]
US 7465787B2 · Wittrup et al. · 2008 [cited by applicant]
US 7569357B2 · Kranz et al. · 2009 [cited by applicant]
US 7700302B2 · Hua et al. · 2010 [cited by applicant]
US 8691225B2 · Schoeberl et al. · 2014 [cited by applicant]
US 8691730B2 · Vasquez et al. · 2014 [cited by applicant]
US 8877688B2 · Vasquez et al. · 2014 [cited by applicant]
US 8927694B2 · McDonagh et al. · 2015 [cited by applicant]
US 8961966B2 · Schoeberl et al. · 2015 [cited by applicant]
US 9464286B2 · Zhu et al. · 2016 [cited by applicant]
US 10189894B2 · Vasquez et al. · 2019 [cited by applicant]
US 10196635B2 · Vasquez et al. · 2019 [cited by applicant]
US 10329555B2 · Zhu et al. · 2019 [cited by applicant]
US 11008383B2 · Vasquez et al. · 2021 [cited by applicant]
US 11008568B2 · Vasquez et al. · 2021 [cited by applicant]
US 20020004215A1 · Osbourn et al. · 2002 [cited by applicant]
US 20020069421A1 · Hale et al. · 2002 [cited by applicant]
US 20020155157A1 · Luo et al. · 2002 [cited by applicant]
US 20020169284A1 · Ashkenazi et al. · 2002 [cited by applicant]
US 20020197691A1 · Sugiyama · 2002 [cited by applicant]
US 20030083474A1 · Schmidt · 2003 [cited by applicant]
US 20030092073A1 · Ambrosius et al. · 2003 [cited by applicant]
US 20030104524A1 · Summers et al. · 2003 [cited by applicant]
US 20030114659A1 · Winter et al. · 2003 [cited by applicant]
US 20030130496A1 · Winter et al. · 2003 [cited by applicant]
US 20030148372A1 · Tomlinson et al. · 2003 [cited by applicant]
US 20030165988A1 · Hua et al. · 2003 [cited by applicant]
US 20030190674A1 · Griffiths et al. · 2003 [cited by applicant]
US 20030224408A1 · Hoogenboom et al. · 2003 [cited by applicant]
US 20030228302A1 · Crea · 2003 [cited by applicant]
US 20030232333A1 · Ladner et al. · 2003 [cited by applicant]
US 20030232395A1 · Hufton · 2003 [cited by applicant]
US 20040038921A1 · Kreutzer et al. · 2004 [cited by applicant]
US 20040082012A1 · Busch et al. · 2004 [cited by applicant]
US 20040110941A2 · Winter et al. · 2004 [cited by applicant]
US 20040146976A1 · Wittrup et al. · 2004 [cited by applicant]
US 20040157214A1 · McCafferty et al. · 2004 [cited by applicant]
US 20040157215A1 · McCafferty et al. · 2004 [cited by applicant]
US 20040175756A1 · Kolkman et al. · 2004 [cited by applicant]
US 20040190333A1 · Yuan et al. · 2004 [cited by applicant]
US 20040197347A1 · Sykes et al. · 2004 [cited by applicant]
US 20040197866A1 · Johnson et al. · 2004 [cited by applicant]
US 20040209317A1 · Ting · 2004 [cited by applicant]
US 20040219611A1 · Racher · 2004 [cited by applicant]
US 20040248298A1 · Schutz et al. · 2004 [cited by applicant]
US 20040259162A1 · Kappel et al. · 2004 [cited by applicant]
US 20050009028A1 · Heintz et al. · 2005 [cited by applicant]
US 20050019827A1 · Diller et al. · 2005 [cited by applicant]
US 20050048512A1 · Kolkman et al. · 2005 [cited by applicant]
US 20050048545A1 · Cull et al. · 2005 [cited by applicant]
US 20050053591A1 · Pun · 2005 [cited by applicant]
US 20050053973A1 · Kolkman et al. · 2005 [cited by applicant]
US 20050058661A1 · Sykes et al. · 2005 [cited by applicant]
US 20050089932A1 · Kolkman et al. · 2005 [cited by applicant]
US 20050164301A1 · Kolkman et al. · 2005 [cited by applicant]
US 20050176070A1 · Auton · 2005 [cited by applicant]
US 20050191710A1 · Hanrahan et al. · 2005 [cited by applicant]
US 20050202512A1 · Tomlinson et al. · 2005 [cited by applicant]
US 20050221384A1 · Kolkman et al. · 2005 [cited by applicant]
US 20050233389A1 · Ting et al. · 2005 [cited by applicant]
US 20050255462A1 · Barrett et al. · 2005 [cited by applicant]
US 20060003334A1 · Achim et al. · 2006 [cited by applicant]
US 20060008883A1 · Lazar et al. · 2006 [cited by applicant]
US 20060019260A1 · Lerner et al. · 2006 [cited by applicant]
US 20060024676A1 · Uhlmann et al. · 2006 [cited by applicant]
US 20060046261A1 · Porter et al. · 2006 [cited by applicant]
US 20060046285A1 · Watzele et al. · 2006 [cited by applicant]
US 20060052294A1 · Otto · 2006 [cited by applicant]
US 20060061754A1 · Turner et al. · 2006 [cited by applicant]
US 20060061755A1 · Turner et al. · 2006 [cited by applicant]
US 20060062531A1 · Turner et al. · 2006 [cited by applicant]
US 20060063264A1 · Turner et al. · 2006 [cited by applicant]
US 20060106199A1 · Erdmann et al. · 2006 [cited by applicant]
US 20060166252A1 · Ladner et al. · 2006 [cited by applicant]
US 20060172281A1 · Schutz et al. · 2006 [cited by applicant]
US 20060177440A1 · Siegel · 2006 [cited by applicant]
US 20060211087A1 · Roosild et al. · 2006 [cited by applicant]
US 20060234302A1 · Hoet et al. · 2006 [cited by applicant]
US 20060257937A1 · Ladner · 2006 [cited by applicant]
US 20070031879A1 · Ley et al. · 2007 [cited by applicant]
US 20070037216A1 · Johnson et al. · 2007 [cited by applicant]
US 20070082330A1 · Barrett et al. · 2007 [cited by applicant]
US 20070099267A1 · Harvey et al. · 2007 [cited by applicant]
US 20070141548A1 · Kohl et al. · 2007 [cited by applicant]
US 20070258954A1 · Iverson et al. · 2007 [cited by applicant]
US 20070275416A1 · Gloeckner et al. · 2007 [cited by applicant]
US 20080053543A1 · Baier et al. · 2008 [cited by applicant]
US 20080053901A1 · Mierendorf et al. · 2008 [cited by applicant]
US 20080053917A1 · Larson et al. · 2008 [cited by applicant]
US 20080064093A1 · Porter et al. · 2008 [cited by applicant]
US 20080153712A1 · Crea · 2008 [cited by applicant]
US 20080171059A1 · Howland et al. · 2008 [cited by applicant]
US 20080206239A1 · Jones et al. · 2008 [cited by applicant]
US 20090082213A1 · Horowitz et al. · 2009 [cited by applicant]
US 20090280560A1 · Wittrup et al. · 2009 [cited by applicant]
US 20100009866A1 · Prinz et al. · 2010 [cited by applicant]
US 20100292103A1 · Ladner · 2010 [cited by applicant]
US 20110009280A1 · Hufton et al. · 2011 [cited by applicant]
US 20110082054A1 · Ladner · 2011 [cited by applicant]
US 20110136695A1 · Crea · 2011 [cited by applicant]
US 20110189183A1 · Williamson et al. · 2011 [cited by applicant]
US 20130046056A1 · Spector et al. · 2013 [cited by applicant]
US 20140031292A1 · Wittrup et al. · 2014 [cited by applicant]
US 20140031522A1 · Li et al. · 2014 [cited by applicant]
US 20140080766A1 · Pirie et al. · 2014 [cited by applicant]
US 20140296434A1 · Spector et al. · 2014 [cited by applicant]
US 20140364340A1 · Vasquez et al. · 2014 [cited by applicant]
US 20150080558A1 · Spector et al. · 2015 [cited by applicant]
US 20160237424A1 · Zhu et al. · 2016 [cited by applicant]
US 20190203205A1 · Vasquez et al. · 2019 [cited by applicant]
US 20190225677A1 · Vasquez et al. · 2019 [cited by applicant]
US 20230399386A1 · Vasquez et al. · 2023 [cited by applicant]
DE 19624562A1 · 1998 [cited by applicant]
EP 0404097A2 · 1990 [cited by applicant]
JP 2004518432A · 2004 [cited by applicant]
WO WO8504330A1 · 1985 [cited by applicant]
WO WO198801649A1 · 1988 [cited by applicant]
WO WO8806630A1 · 1988 [cited by applicant]
WO WO1990007380A2 · 1990 [cited by applicant]
WO WO9311161A1 · 1993 [cited by applicant]
WO WO9407922A1 · 1994 [cited by applicant]
WO WO9526400A1 · 1995 [cited by applicant]
WO WO9607754A1 · 1996 [cited by applicant]
WO WO9708320A1 · 1997 [cited by applicant]
WO WO9720923A1 · 1997 [cited by applicant]
WO WO9749809A1 · 1997 [cited by applicant]
WO WO9849198A1 · 1998 [cited by applicant]
WO WO199852976A1 · 1998 [cited by applicant]
WO WO9906834A2 · 1999 [cited by applicant]
WO WO9928502A1 · 1999 [cited by applicant]
WO WO9936569A1 · 1999 [cited by applicant]
WO WO9950461A1 · 1999 [cited by applicant]
WO WO9953049A1 · 1999 [cited by applicant]
WO WO9955367A1 · 1999 [cited by applicant]
WO WO0018905A1 · 2000 [cited by applicant]
WO WO0054057A1 · 2000 [cited by applicant]
WO WO0179229A2 · 2001 [cited by applicant]
WO WO0179481A2 · 2001 [cited by applicant]
WO WO02061071A2 · 2002 [cited by applicant]
WO WO2004101790A1 · 2004 [cited by applicant]
WO WO2005007121A2 · 2005 [cited by applicant]
WO WO2005023993A2 · 2005 [cited by applicant]
WO WO2006138700A2 · 2006 [cited by applicant]
WO WO2007056441A2 · 2007 [cited by applicant]
WO WO2007094842A2 · 2007 [cited by applicant]
WO WO2007106456A2 · 2007 [cited by applicant]
WO WO2008019366A2 · 2008 [cited by applicant]
WO WO2008053275A2 · 2008 [cited by applicant]
WO WO2008067547A2 · 2008 [cited by applicant]
WO WO0936379A2 · 2009 [cited by applicant]
WO WO2010005863A1 · 2010 [cited by applicant]
Knappik et al. (Feb. 11, 2000) Journal of Molecular Biology vol. 296 pp. 57 to 86 (Year: 2000). [cited by examiner]
Rader et al. (Jul. 21, 1998) PNAS USA vol. 95 pp. 8910 to 8915 (Year: 1998). [cited by examiner]
Abbas, A.K. et al., Cellular and Molecular Immunology 4th Ed. W.B. Saunders Company, p. 133 (2000). [cited by applicant]
Adams, G.P. and Schier, R., Generating Improved Single-Chain Fv Molecules For Tumor Targeting, Journal of Immunological Methods, 231:249-260 (1999). [cited by applicant]
Adams, G.P. and Weiner, L. M., “Monoclonal antibody therapy of cancer” Nature Biotechnology, 23(9) 1147-1157 (2005). [cited by applicant]
Adimab Clean Copy of Claims, Filed in Interference No. 105,809, Filed May 19, 2011, pp. 1-5. [cited by applicant]
Adimab Current List of Exhibits, Filed in Interference No. 105,809, Filed Jan. 20, 2012, pp. 1-8. [cited by applicant]
Adimab Current List of Exhibits, Filed in Interference No. 105,809, Filed Sep. 30, 2011, pp. 1-5. [cited by applicant]
Adimab Designation of Lead and Backup Counsel, Filed in Interference No. 105,809, Filed May 19, 2011, pp. 1-6. [cited by applicant]
Adimab Exhibit 2001, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Pat. No. 7,700,302 Issued May 19, 1992, pp. 1-69. [cited by applicant]
Adimab Exhibit 2002, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Boder and Wittrup—Boder et al.“Yeast surface display for screening combinatorial polypeptide libraries” Nature Biotechnology 15:553-557 (1997). [cited by applicant]
Adimab Exhibit 2003, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Boder and Wittrup “Yeast Surface Display for Directed Evolution of Protein Expression, Affinity, and Stability” Methods Enzymol 328:430-444 (20… [cited by applicant]
Adimab Exhibit 2004, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Schreuder et al., “Immobilizing proteins on the surface of yeast cells” Trends Biotechnol. 14(4)115-120 (1996). [cited by applicant]
Adimab Exhibit 2005, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Liu et al. “Rapid Construction of Recombinant DNA by the Univector Plasmid-Fusion System” Methods Enzymol. 328:530-549 (2000). [cited by applicant]
Adimab Exhibit 2006, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Walhout et al., “Gateway Recombinational Cloning: Application to the Cloning of Large Numbers of Open Reading Frames or ORFeomes” Methods Enzym… [cited by applicant]
Adimab Exhibit 2007, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Smith, G. “Homologous Recombination Near and Far from DNA Breaks: Alternative Roles and Contrasting Views” Annu Rev Genet 35:243-274 (2001). [cited by applicant]
Adimab Exhibit 2008, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Declaration of David M. Kranz, Ph.D, pp. 1-8. [cited by applicant]
Adimab Exhibit 2009, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Sauer, B. “Inducible Gene Targeting in Mice Using the Crd / lox System” Methods 14(4)381-392 (1998). [cited by applicant]
Adimab Exhibit 2010, Filed in Interference No. 105,809, Filed Aug. 19, 2011—WO 03/02956 Published Apr. 10, 2003, pp. 1-138. [cited by applicant]
Adimab Exhibit 2011, Filed in Interference No. 105,809, Filed Aug. 19, 2011—EP 02766425 Amendment before Examination filed Jun. 16, 2004, pp. 1-18. [cited by applicant]
Adimab Exhibit 2012, Filed in Interference number 105,809, Filed Aug. 19, 2011—EP Publication No. EP1438400 Published Jun. 17, 2009, pp. 1-85. [cited by applicant]
Adimab Exhibit 2013, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 10,26264: Non-Final Rejection Issued Dec. 13, 2007, pp. 1-12. [cited by applicant]
Adimab Exhibit 2014, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Pogue and Goodnow—“Gene Dose-dependent Maturation and Receptor Editing of B Cells Expressing Immunoglobulin (Ig)G1 or IgM/IgG1 Tail Antigen Rec… [cited by applicant]
Adimab Exhibit 2015, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 10/262,646: Amendment in Reply to Action of Sep. 7, 2006, pp. 1-26. [cited by applicant]
Adimab Exhibit 2016, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 10/262,646: Amendment in Reply to Action of Dec. 13, 2007, pp. 1-26. [cited by applicant]
Adimab Exhibit 2017, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Swers et al., “Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display” Nucleic Acids Research 32(3) … [cited by applicant]
Adimab Exhibit 2018, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 12/625,337: Dyax's Third Preliminary Amendment and Suggestion of Interference under 37 C.F.R. § 41.202(a) filed Jan. 24, 2011, p… [cited by applicant]
Adimab Exhibit 2019, Filed in Interference No. 105,809, Filed Aug. 19, 2011— [cited by applicant]
Adimab Exhibit 2020, Filed in Interference No. 105,809, Filed Aug. 19, 2011— [cited by applicant]
Adimab Exhibit 2021, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 10/818,920: Ex parte [cited by applicant]
Adimab Exhibit 2022, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Dyax Motions List filed Jun. 28, 2011, pp. 1-10. [cited by applicant]
Adimab Exhibit 2023, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 10/262,646: Final Rejection Issued Oct. 3, 2008, pp. 1-14. [cited by applicant]
Adimab Exhibit 2024, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 10/262,646: Amendment in Reply to Action of Oct. 3, 2008 filed Apr. 3, 2009, pp. 1-13. [cited by applicant]
Adimab Exhibit 2025, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 12/625,337: Amendment and Response to Notice to File Missing Parts filed Aug. 17, 2010, pp. 1-36. [cited by applicant]
Adimab Exhibit 2026, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 09/703,399, filed Oct. 31, 2000, pp. 1-190. [cited by applicant]
Adimab Exhibit 2027, Filed in Interference No. 105,809, Filed Aug. 19, 2011—USSN 2011/0009280 Published Jan. 13, 2011, pp. 1-58. [cited by applicant]
Adimab Exhibit 2028, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Adimab's Reissue U.S. Appl. No. 13/213,302, filed Aug. 19, 2011, pp. 1-90. [cited by applicant]
Adimab Exhibit 2029, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Pat. No. 7,700,302: Amendment in Accordance with 37 C.F.R. §1.73(b) filed Aug. 19, 2011, pp. 1-17. [cited by applicant]
Adimab Exhibit 2030, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Dyax's U.S. Appl. No. 10/262,646, filed Sep. 30, 2002, pp. 1-138. [cited by applicant]
Adimab Exhibit 2031, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Dyax's U.S. Appl. No. 60/326,320, filed Oct. 1, 2001, pp. 1-90. [cited by applicant]
Adimab Exhibit 2032, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Adimab's U.S. Appl. No. 11/593,957, filed Nov. 6, 2006, pp. 1-125. [cited by applicant]
Adimab Exhibit 2033, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Adimab's U.S. Appl. No. 10/360,828, filed Feb. 7, 2003, pp. 1-135. [cited by applicant]
Adimab Exhibit 2034, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Adimab's U.S. Appl. No. 10/133,978, filed Apr. 25, 2002, pp. 138. [cited by applicant]
Adimab Exhibit 2035, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Adimab's U.S. Appl. No. 10/072,301, filed Feb. 8, 2002, pp. 1-123. [cited by applicant]
Adimab Exhibit 2036, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Adimab's U.S. Appl. No. 10/071,866, filed Feb. 8, 2002, pp. 1-132. [cited by applicant]
Adimab Exhibit 2037, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 12/625,337, filed Nov. 24, 2009, pp. 1-164. [cited by applicant]
Adimab Exhibit 2038, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Assignment for U.S. Pat. No. 7,700,302 filed Nov. 6, 2006, pp. 1. [cited by applicant]
Adimab Exhibit 2039, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Filing Receipt for U.S. Appl. No. 11/593,957 dated Dec. 4, 2006, pp. 1-3. [cited by applicant]
Adimab Exhibit 2040, Filed in Interference No. 105,809, Filed Aug. 19, 2011—Hua et al., “Minimum Length of Sequence Homology Required for in Vivo Cloning by Homologous Recombination in Yeast” Plasmid 38:91-96 (1997). [cited by applicant]
Adimab Exhibit 2041, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 10/262,646: Notice of Abandonment dated Dec. 10, 2009, pp. 1-2. [cited by applicant]
Adimab Exhibit 2042, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 10/133,978: Office Action Restricing Claims dated Oct. 5, 2004, pp. 1-19. [cited by applicant]
Adimab Exhibit 2043, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 09/703,399 Complete File History, pp. 1-758. [cited by applicant]
Adimab Exhibit 2044, Filed in Interference No. 105,809, Filed Aug. 19, 2011—U.S. Appl. No. 13/213,302 Second Amendment to Introduce Missing Drawing Sheets filed on Aug. 19, 2011, pp. 1-9. [cited by applicant]
Adimab Exhibit 2045, Filed in Interference No. 105,809, Filed Sep. 30, 2011—U.S. Pat. No. 7,138,496 Issued Nov. 21, 2006, pp. 1-70. [cited by applicant]
Adimab Exhibit 2046, Filed in Interference No. 105,809, Filed Sep. 30, 2011—U.S. Pat. No. 7,005,503 Issued Feb. 28, 2006, pp. 1-63. [cited by applicant]
Adimab Exhibit 2047, Filed in Interference No. 105,809, Filed Sep. 30, 2011—U.S. Appl. No. 13/249,581: Complete File History of the CON of Reissue, pp. 1-113. [cited by applicant]
Adimab Exhibit 2048, Filed in Interference No. 105,809, Filed Sep. 30, 2011—U.S. Appl. No. 13/213,302: Fourth Preliminary Amendment filed Aug. 19, 2011, pp. 1-78. [cited by applicant]
Adimab Exhibit 2049, Filed in Interference No. 105,809, Filed Sep. 30, 2011—U.S. Pat. No. 6,610,472 Issued Aug. 26, 2003, pp. 1-72. [cited by applicant]
Adimab Exhibit 2050, Filed in Interference No. 105,809, Filed Sep. 30, 2011—U.S. Appl. No. 13/213/302: Third Preliminary Amendment filed Aug. 19, 2011, pp. 1-9. [cited by applicant]
Adimab Exhibit 2051, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Horwitz et al., “Secretion of functional antibody and Fab fragment from yeast cells” Proc. Natl. Acad. Sci. 85:8678-8682 (1988). [cited by applicant]
Adimab Exhibit 2052, Filed in Interference No. 105,809, Filed Nov. 21, 2011—US Publication No. 2003/0232395 Published Dec. 18, 2003, pp. 1-39. [cited by applicant]
Adimab Exhibit 2053, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Website of Nathalie Scholler, MD., Ph.D, pp. 1-3. [cited by applicant]
Adimab Exhibit 2054, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Raymond et al., “General Method for Plasmid Construction Using Homologous Recombination” BioTechniques 26:pp. 1-6 (1999). [cited by applicant]
Adimab Exhibit 2055, Filed in Interference No. 105,809, Filed Nov. 21, 2011—U.S. Pat. No. 6,300,065 Issued Oct. 9, 2001, pp. 1-67. [cited by applicant]
Adimab Exhibit 2056, Filed in Interference No. 105,809, Filed Nov. 21, 2011—U.S. Pat. No. 6,027,910 Issued Feb. 22, 2000, pp. 1-58. [cited by applicant]
Adimab Exhibit 2057, Filed in Interference No. 105,809, Filed Nov. 21, 2011—U.S. Pat. No. 6,696,251 Issued Feb. 24, 2004, pp. 1-57. [cited by applicant]
Adimab Exhibit 2058, Filed in Interference No. 105,809, Filed Nov. 21, 2011—International Publication No. WO 94/18330 Published Aug. 18, 1994, pp. 1-69. [cited by applicant]
Adimab Exhibit 2059, Filed in Interference No. 105,809, Filed Nov. 21, 2011—U.S. Pat. No. 6,114,147 Issued Sep. 5, 2000, pp. 1-40. [cited by applicant]
Adimab Exhibit 2060, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Schreuder et al., “Targeting of a Heterologous Protein to the Cell Wall of [cited by applicant]
Adimab Exhibit 2061, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Imai and Yamamoto “The fission yeast mating pheromone P-factor: its molecular structure, gene structure, and ability to induce gene expression … [cited by applicant]
Adimab Exhibit 2062, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Cappellaro et al “Mating type-specific cell-cell recognition of [cited by applicant]
Adimab Exhibit 2063, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Van der vaart et al., “Comparison of Cell Wall Proteins of [cited by applicant]
Adimab Exhibit 2064, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Murai et al., “Construction of a Starch-Utilizing Yeast by Cell Surface Engineering” Applied and Environmental Microbiology 63(4):1362-1366 (19… [cited by applicant]
Adimab Exhibit 2065, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Ueda and Tanaka “Cell Surface Engineering of Yeast: Construction of Arming Yeast with Biocatalyst” Journal of Bioscience and Bioengineering 90(… [cited by applicant]
Adimab Exhibit 2066, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Shibasaki et al., “Construction of an engineered yeast with glucose-inducible emission of green fluorescence from the cell surface” Applied Mic… [cited by applicant]
Adimab Exhibit 2067, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Boder and Wittrup “Yeast surface display system for antibody engineeirng” pp. 283 (1996). [cited by applicant]
Adimab Exhibit 2068, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Deposition of David M. Kranz, Ph.D. dated Oct. 14, 2011, pp. 1-167. [cited by applicant]
Adimab Exhibit 2069, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Depostion of Nathalie Scholler, M.D., Ph. D. dated Oct. 24, 2011, pp. 1-193. [cited by applicant]
Adimab Exhibit 2070, Filed in Interference No. 105,809, Filed Nov. 21, 2011—U.S. Pat. No. 6,699,658 Issued Mar. 2, 2004, pp. 1-61. [cited by applicant]
Adimab Exhibit 2071, Filed in Interference No. 105,809, Filed Nov. 21, 2011—U.S. Pat. No. 7,208,293 Issued Apr. 24, 2007, pp. 1-282. [cited by applicant]
Adimab Exhibit 2072, Filed in Interference No. 105,809, Filed Nov. 21, 2011—International Publication No. WO 94/01567 Published Jan. 20, 1994, pp. 1-101. [cited by applicant]
Adimab Exhibit 2073, Filed in Interference No. 105,809, Filed Nov. 21, 2011—U.S. Pat. No. 6,423,538 Issued Jul. 23, 2002, pp. 1-60. [cited by applicant]
Adimab Exhibit 2074, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Hendershot and Sitia “Immunoglobulin Assembly and Secretion” Molecular Biology of B Cells, Chapter 17 pp. 261-273 (2004). [cited by applicant]
Adimab Exhibit 2075, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Hoogenboom and Chames “Natural and designer binding sites made by phage display technology” Immunology Today 21(8):371-378 (2000). [cited by applicant]
Adimab Exhibit 2076, Filed in Interference No. 105,809, Filed Nov. 21, 2011—U.S. Appl. No. 11/593,957 Notice of Allowance dated Nov. 19, 2009, pp. 1-7. [cited by applicant]
Adimab Exhibit 2077, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Declaration of Eric T. Boder, Ph.D. filed Nov. 21, 2011, pp. 1-12. [cited by applicant]
Adimab Exhibit 2078, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Second Declaration of David M. Kranz, Ph.D. filed Nov. 21, 2011, pp. 1-27. [cited by applicant]
Adimab Exhibit 2079, Filed in Interference No. 105,809, Filed Nov. 21, 2011—U.S. Appl. No. 13/300,340: Reissue Application filed Nov. 18, 2011, pp. 1-86. [cited by applicant]
Adimab Exhibit 2080 [corrected], Filed in Interference 105,809, Filed Nov. 21, 2011—U.S. Appl. No. 13/300,308: [corrected] Reissue Application filed Nov. 18, 2011. pp. 1-95. [cited by applicant]
Adimab Exhibit 2081, Filed in Interference No. 105,809, Filed Nov. 21, 2011—Declaration of James Sheridan, Ph.D. filed Nov. 21, 2011, pp. 1-4. [cited by applicant]
Adimab Exhibit 2082, Filed in Interference No. 105,809, Filed Nov. 21, 2011— [cited by applicant]
Adimab Exhibit 2083, Filed in Interference No. 105,809, Filed Nov. 21, 2011— [cited by applicant]
Adimab Exhibit 2084, Filed in Interference No. 105,809, Filed Nov. 21, 2011—U.S. Pat. No. 5,223,409 Issued Jun. 29, 1993, pp. 1-217. [cited by applicant]